董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarah Boyce | 女 | Director | 51 | 4.12万美元 | 未持股 | 2023-04-10 |
| Joshua Tamaroff | 男 | Director | 37 | 22.58万美元 | 未持股 | 2023-04-10 |
| Matthew W. Foehr | 男 | President, Chief Executive Officer and Director | 50 | 未披露 | 未持股 | 2023-04-10 |
| Jennifer Cochran | 女 | Director | 51 | 14.82万美元 | 34.81 | 2023-04-10 |
| Sarah Boyce | 女 | Director | 51 | 未披露 | 未持股 | 2023-04-10 |
| Sunil Patel | 男 | Director | 51 | 未披露 | 未持股 | 2023-04-10 |
| Carolyn Bertozzi | 女 | Director | 56 | 14.82万美元 | 28.89 | 2023-04-10 |
| John Higgins | 男 | Chairperson of the Board | 53 | 15.07万美元 | 417.67 | 2023-04-10 |
| Joshua Tamaroff | 男 | Director | 37 | 未披露 | 未持股 | 2023-04-10 |
| Sunil Patel | 男 | Director | 51 | 1.29万美元 | 未持股 | 2023-04-10 |
| Matthew W. Foehr | 男 | President, Chief Executive Officer and Director | 50 | 381.17万美元 | 504.96 | 2023-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Matthew W. Foehr | 男 | President, Chief Executive Officer and Director | 50 | 未披露 | 未持股 | 2023-04-10 |
| Kurt A. Gustafson | 男 | Executive Vice President, Finance and Chief Financial Officer | 54 | 未披露 | 未持股 | 2023-04-10 |
| Charles S. Berkman | 男 | Chief Legal Officer and Secretary | 54 | 未披露 | 未持股 | 2023-04-10 |
| Charles S. Berkman | 男 | Chief Legal Officer and Secretary | 54 | 162.44万美元 | 103.96 | 2023-04-10 |
| Matthew W. Foehr | 男 | President, Chief Executive Officer and Director | 50 | 381.17万美元 | 504.96 | 2023-04-10 |
| Kurt A. Gustafson | 男 | Executive Vice President, Finance and Chief Financial Officer | 55 | 161.31万美元 | 114.92 | 2023-04-10 |
董事简历
中英对照 | 中文 | 英文- Sarah Boyce
-
Sarah Boyce在2015年1月加入Isis担任Phenomex Inc.的首席商务官。在加入Isis之前（2012-2014年）她是Forest Laboratories股份有限公司（Forest Laboratories, Inc）副总裁和国际商务战略和运营负责人。2010-2011年她是Alexion Pharmaceuticals副总裁和肾脏病治疗领域的全球负责人。2000-2010年她在Novartis Group AG担任不同的职位，包括副总裁，儿科与专业的全球项目负责人。在那之前，她在Bayer Pharmaceuticals and Roche担任不同职位。
Sarah Boyce has served as President and Chief Executive Officer and as a member of board of directors since October 2019. Prior to joining Avidity, she served as President and a member of the board of directors of Akcea Therapeutics, Inc. from April 2018 through September 2019, where she led the commercialization of the company's rare disease products. Ms. Boyce served as Chief Biness Officer of Ionis Pharmaceuticals, Inc. from January 2015 to April 2018, and Vice President, Head of International Biness Strategy and Operations at Forest Laboratories, Inc. from 2012 to 2014. She previoly held vario positions with Alexion Pharmaceuticals Inc., Novartis AG, Bayer AG and F. Hoffmann La Roche AG. Ms. Boyce has served on the boards of directors of Abcuro, Inc., a privately held biotechnology company, since July 2024, and of Contineum Therapeutics, Inc. since June 2024. Ms. Boyce also served on the boards of directors of OmniAb, Inc. from November 2022 to April 2025, of Berkeley Lights Inc. from July 2019 to May 2022 and of Ligand Pharmaceuticals Incorporated from October 2019 to November 2022. Ms. Boyce holds a B.S. in Microbiology from the University of Manchester, England. Ms. Boyce's knowledge of biness, as ll as her extensive development, commercial and executive management experience, contributed to board of directors' conclion that she should serve as a director of company. - Sarah Boyce在2015年1月加入Isis担任Phenomex Inc.的首席商务官。在加入Isis之前（2012-2014年）她是Forest Laboratories股份有限公司（Forest Laboratories, Inc）副总裁和国际商务战略和运营负责人。2010-2011年她是Alexion Pharmaceuticals副总裁和肾脏病治疗领域的全球负责人。2000-2010年她在Novartis Group AG担任不同的职位，包括副总裁，儿科与专业的全球项目负责人。在那之前，她在Bayer Pharmaceuticals and Roche担任不同职位。
- Sarah Boyce has served as President and Chief Executive Officer and as a member of board of directors since October 2019. Prior to joining Avidity, she served as President and a member of the board of directors of Akcea Therapeutics, Inc. from April 2018 through September 2019, where she led the commercialization of the company's rare disease products. Ms. Boyce served as Chief Biness Officer of Ionis Pharmaceuticals, Inc. from January 2015 to April 2018, and Vice President, Head of International Biness Strategy and Operations at Forest Laboratories, Inc. from 2012 to 2014. She previoly held vario positions with Alexion Pharmaceuticals Inc., Novartis AG, Bayer AG and F. Hoffmann La Roche AG. Ms. Boyce has served on the boards of directors of Abcuro, Inc., a privately held biotechnology company, since July 2024, and of Contineum Therapeutics, Inc. since June 2024. Ms. Boyce also served on the boards of directors of OmniAb, Inc. from November 2022 to April 2025, of Berkeley Lights Inc. from July 2019 to May 2022 and of Ligand Pharmaceuticals Incorporated from October 2019 to November 2022. Ms. Boyce holds a B.S. in Microbiology from the University of Manchester, England. Ms. Boyce's knowledge of biness, as ll as her extensive development, commercial and executive management experience, contributed to board of directors' conclion that she should serve as a director of company.
- Joshua Tamaroff
-
Joshua Tamaroff自2018年以来一直是我们的董事会成员。Tamaroff先生于2009年加入Avista，并担任校长。在加入Avista之前，Tamaroff先生在雷曼兄弟（Lehman Brothers）和巴克莱资本（Barclays Capital）担任杠杆金融集团的分析师。Tamaroff先生目前担任Cosette Pharmaceuticals，Inc.、GCM Holding Corporation和United BioSource Corporation的董事，此前曾担任InvestorPlace Media、IWCO Direct、OptiNose，Inc.的董事。纳斯达克股票代码:OPTN和WideOpenWest，Inc.（NYSE:WOW）。Tamaroff先生在康奈尔大学（Cornell University）获得理学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位，在那里他是一名帕尔默学者。
Joshua Tamaroff has been a member of our board of directors since 2018. Mr. Tamaroff joined Avista in 2009 and serves as a Principal. Prior to joining Avista, Mr. Tamaroff worked as an Analyst in the leveraged finance group at Lehman Brothers and Barclays Capital. Mr. Tamaroff currently serves as a director of Cosette Pharmaceuticals, Inc., GCM Holding Corporation and United BioSource Corporation, and previously served as a director of InvestorPlace Media, IWCO Direct, OptiNose, Inc. NASDAQ: OPTN and WideOpenWest, Inc. (NYSE: WOW). Mr. Tamaroff received a Bachelor of Science from Cornell University and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was a Palmer Scholar. - Joshua Tamaroff自2018年以来一直是我们的董事会成员。Tamaroff先生于2009年加入Avista，并担任校长。在加入Avista之前，Tamaroff先生在雷曼兄弟（Lehman Brothers）和巴克莱资本（Barclays Capital）担任杠杆金融集团的分析师。Tamaroff先生目前担任Cosette Pharmaceuticals，Inc.、GCM Holding Corporation和United BioSource Corporation的董事，此前曾担任InvestorPlace Media、IWCO Direct、OptiNose，Inc.的董事。纳斯达克股票代码:OPTN和WideOpenWest，Inc.（NYSE:WOW）。Tamaroff先生在康奈尔大学（Cornell University）获得理学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位，在那里他是一名帕尔默学者。
- Joshua Tamaroff has been a member of our board of directors since 2018. Mr. Tamaroff joined Avista in 2009 and serves as a Principal. Prior to joining Avista, Mr. Tamaroff worked as an Analyst in the leveraged finance group at Lehman Brothers and Barclays Capital. Mr. Tamaroff currently serves as a director of Cosette Pharmaceuticals, Inc., GCM Holding Corporation and United BioSource Corporation, and previously served as a director of InvestorPlace Media, IWCO Direct, OptiNose, Inc. NASDAQ: OPTN and WideOpenWest, Inc. (NYSE: WOW). Mr. Tamaroff received a Bachelor of Science from Cornell University and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was a Palmer Scholar.
- Matthew W. Foehr
-
Matthew W. Foehr是总裁兼首席执行官，也是Omniab，Inc.董事会成员，在管理运营、技术开发和全球研发计划方面拥有超过25年的制药行业经验。Foehr先生此前曾于2015年至2022年担任Ligand制药公司的总裁兼首席运营官，在此之前，自2011年起担任Ligand的执行副总裁兼首席运营官。在加入Ligand之前，他是葛兰素史克Stiefel事业部的副总裁兼消费者皮肤病学研发主管，以及皮肤病学代理首席科学官。继GSK于2009年收购Stiefel后，Foehr先生领导了Stiefel与GSK的研发整合。在Stiefel Laboratories，Foehr先生曾担任全球研发运营高级副总裁、产品开发与支持高级副总裁以及全球供应链技术服务副总裁。在加入Stiefel之前，Foehr先生曾在Connetics Corporation担任多个执行职务，包括技术运营高级副总裁和制造副总裁。Foehr先生在Viking Therapeutics, Inc.（一家上市的生物技术公司）的董事会任职，并于2015年起担任Ritter Pharmaceuticals，Inc.的董事，直到该公司于2020年与Qualigen治疗，Inc.合并。Foehr先生在圣克拉拉大学获得生物学学士学位。
Matthew W. Foehr,is President and Chief Executive Officer and a member of Omniab, Inc. board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020.Mr. Foehr received his BS degree in biology from Santa Clara University. - Matthew W. Foehr是总裁兼首席执行官，也是Omniab，Inc.董事会成员，在管理运营、技术开发和全球研发计划方面拥有超过25年的制药行业经验。Foehr先生此前曾于2015年至2022年担任Ligand制药公司的总裁兼首席运营官，在此之前，自2011年起担任Ligand的执行副总裁兼首席运营官。在加入Ligand之前，他是葛兰素史克Stiefel事业部的副总裁兼消费者皮肤病学研发主管，以及皮肤病学代理首席科学官。继GSK于2009年收购Stiefel后，Foehr先生领导了Stiefel与GSK的研发整合。在Stiefel Laboratories，Foehr先生曾担任全球研发运营高级副总裁、产品开发与支持高级副总裁以及全球供应链技术服务副总裁。在加入Stiefel之前，Foehr先生曾在Connetics Corporation担任多个执行职务，包括技术运营高级副总裁和制造副总裁。Foehr先生在Viking Therapeutics, Inc.（一家上市的生物技术公司）的董事会任职，并于2015年起担任Ritter Pharmaceuticals，Inc.的董事，直到该公司于2020年与Qualigen治疗，Inc.合并。Foehr先生在圣克拉拉大学获得生物学学士学位。
- Matthew W. Foehr,is President and Chief Executive Officer and a member of Omniab, Inc. board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020.Mr. Foehr received his BS degree in biology from Santa Clara University.
- Jennifer Cochran
-
詹妮弗·科克伦（Jennifer Cochran）自2005年以来在斯坦福大学担任过多个职务，目前担任生物工程教授和（通过礼遇）化学工程教授（2005年1月被任命为助理教授，2018年晋升为教授），并担任生物工程的Shriram主席，她自2017年9月以来一直担任该职位。科克伦博士还担任红树风险投资公司的首席科学顾问，这是一家专注于生命科学的投资基金，自她于2020年8月共同创立该基金以来。Cochran博士还在2015年10月至2020年4月期间担任Lagunita Biosciences的首席科学家，该公司是一家医疗保健投资公司和孵化器。在加入斯坦福大学之前，她曾在麻省理工学院担任多个研究职位，最近担任博士后研究员。Cochran博士目前在私营生物技术公司Virsti Therapeutics，Inc.、Revel Pharmaceuticals和Trapeze Therapeutics，Inc.的董事会任职。她还曾在私营生物技术公司Nodus Therapeutics，Inc.和Combangio，Inc.以及xCella Biosciences的董事会任职，直至2020年被Ligand收购。Cochran博士获得特拉华大学生物化学学士学位和麻省理工学院生物化学博士学位。
Jennifer Cochran,has served in numerous roles at Stanford University since 2005, where she is currently a Professor of Bioengineering and (by courtesy) of Chemical Engineering (appointed to the faculty as an Assistant Professor in January 2005, promoted to Professor in 2018), and the Shriram Chair of Bioengineering, a position she has held since September 2017. Dr. Cochran also serves as the Chief Scientific Advisor to Red Tree Venture Capital, a life-sciences-focused investment fund, since she co-founded it in August 2020. Dr. Cochran was also the Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, from October 2015 to April 2020. Prior to Stanford, she held several research positions at the Massachusetts Institute of Technology, most recently as a Postdoctoral Fellow. Dr. Cochran currently serves on the boards of directors of privately-held biotechnology companies Virsti Therapeutics, Inc., Revel Pharmaceuticals, and Trapeze Therapeutics, Inc. She has also served on the boards of directors of privately-held biotechnology companies Nodus Therapeutics, Inc. and Combangio, Inc., as well as xCella Biosciences until its acquisition by Ligand in 2020.Dr. Cochran received a B.S. degree in biochemistry from the University of Delaware and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology. - 詹妮弗·科克伦（Jennifer Cochran）自2005年以来在斯坦福大学担任过多个职务，目前担任生物工程教授和（通过礼遇）化学工程教授（2005年1月被任命为助理教授，2018年晋升为教授），并担任生物工程的Shriram主席，她自2017年9月以来一直担任该职位。科克伦博士还担任红树风险投资公司的首席科学顾问，这是一家专注于生命科学的投资基金，自她于2020年8月共同创立该基金以来。Cochran博士还在2015年10月至2020年4月期间担任Lagunita Biosciences的首席科学家，该公司是一家医疗保健投资公司和孵化器。在加入斯坦福大学之前，她曾在麻省理工学院担任多个研究职位，最近担任博士后研究员。Cochran博士目前在私营生物技术公司Virsti Therapeutics，Inc.、Revel Pharmaceuticals和Trapeze Therapeutics，Inc.的董事会任职。她还曾在私营生物技术公司Nodus Therapeutics，Inc.和Combangio，Inc.以及xCella Biosciences的董事会任职，直至2020年被Ligand收购。Cochran博士获得特拉华大学生物化学学士学位和麻省理工学院生物化学博士学位。
- Jennifer Cochran,has served in numerous roles at Stanford University since 2005, where she is currently a Professor of Bioengineering and (by courtesy) of Chemical Engineering (appointed to the faculty as an Assistant Professor in January 2005, promoted to Professor in 2018), and the Shriram Chair of Bioengineering, a position she has held since September 2017. Dr. Cochran also serves as the Chief Scientific Advisor to Red Tree Venture Capital, a life-sciences-focused investment fund, since she co-founded it in August 2020. Dr. Cochran was also the Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, from October 2015 to April 2020. Prior to Stanford, she held several research positions at the Massachusetts Institute of Technology, most recently as a Postdoctoral Fellow. Dr. Cochran currently serves on the boards of directors of privately-held biotechnology companies Virsti Therapeutics, Inc., Revel Pharmaceuticals, and Trapeze Therapeutics, Inc. She has also served on the boards of directors of privately-held biotechnology companies Nodus Therapeutics, Inc. and Combangio, Inc., as well as xCella Biosciences until its acquisition by Ligand in 2020.Dr. Cochran received a B.S. degree in biochemistry from the University of Delaware and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology.
- Sarah Boyce
-
Sarah Boyce，自2019年10月起担任上市生物技术公司Avidity Biosciences, Inc.的总裁兼首席执行官。在加入Avidity之前，她于2018年4月至2019年9月期间担任Akcea治疗（纳斯达克：AKCA）的董事兼总裁，该公司是一家上市生物制药公司，专注于严重和罕见疾病。Boyce女士于2015年1月至2018年4月在伊奥尼斯制药公司（纳斯达克：IONS）担任首席商务官，负责业务发展、联盟管理、患者宣传和投资者关系。在加入Ionis之前，她曾在森林实验室担任副总裁、国际业务战略和运营主管。Boyce女士曾在亚力兄制药公司、诺华集团股份有限公司（纽约证券交易所代码：NVS）、拜耳公司和F. Hoffmann-La Roche AG担任过多个职位。Boyce女士还曾于2019年7月至2022年5月期间在上市生物制药公司Berkeley Lights Inc.（纳斯达克：BLI）的董事会任职。Boyce女士获得英国曼彻斯特大学微生物学学士学位。
Sarah Boyce,has served as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-traded biotechnology company, since October 2019. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics (Nasdaq: AKCA), a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April 2018 through September 2019. Ms. Boyce served as Chief Business Officer at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) from January 2015 to April 2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to joining Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. Ms. Boyce held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG (NYSE: NVS), Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also served on the board of directors of Berkeley Lights Inc. (Nasdaq: BLI), a publicly-held biopharmaceutical company, from July 2019 until May 2022.Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England. - Sarah Boyce，自2019年10月起担任上市生物技术公司Avidity Biosciences, Inc.的总裁兼首席执行官。在加入Avidity之前，她于2018年4月至2019年9月期间担任Akcea治疗（纳斯达克：AKCA）的董事兼总裁，该公司是一家上市生物制药公司，专注于严重和罕见疾病。Boyce女士于2015年1月至2018年4月在伊奥尼斯制药公司（纳斯达克：IONS）担任首席商务官，负责业务发展、联盟管理、患者宣传和投资者关系。在加入Ionis之前，她曾在森林实验室担任副总裁、国际业务战略和运营主管。Boyce女士曾在亚力兄制药公司、诺华集团股份有限公司（纽约证券交易所代码：NVS）、拜耳公司和F. Hoffmann-La Roche AG担任过多个职位。Boyce女士还曾于2019年7月至2022年5月期间在上市生物制药公司Berkeley Lights Inc.（纳斯达克：BLI）的董事会任职。Boyce女士获得英国曼彻斯特大学微生物学学士学位。
- Sarah Boyce,has served as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-traded biotechnology company, since October 2019. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics (Nasdaq: AKCA), a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April 2018 through September 2019. Ms. Boyce served as Chief Business Officer at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) from January 2015 to April 2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to joining Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. Ms. Boyce held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG (NYSE: NVS), Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also served on the board of directors of Berkeley Lights Inc. (Nasdaq: BLI), a publicly-held biopharmaceutical company, from July 2019 until May 2022.Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England.
- Sunil Patel
-
Sunil Patel，在生物技术行业拥有20多年的高级管理人员和研发经验。自2018年3月以来，Patel先生一直担任生物技术公司的独立顾问，为战略和企业发展计划提供建议。2009年至2018年3月，Patel先生在OncoMed Pharmaceuticals，Inc.（纳斯达克：OMED）（一家上市的生物技术公司）担任高管职务，负责增加职责，最近担任执行副总裁兼首席财务官。Patel先生曾在BiPar Sciences，Inc.、Allos Therapeutics, Inc.、Connetics、Abgenix，Inc.和吉利德科学 Inc.（GILD）担任企业发展、市场营销和战略方面的高级管理职务。Patel先生还曾任职于麦肯锡公司，为生物技术和制药客户提供服务，曾在ZymoGenetics，Inc.和ProCyte Corporation担任科研职务。帕特尔在加州大学伯克利分校获得化学本科学位，在华盛顿大学获得分子生物工程/生物技术硕士学位。
Sunil Patel,has more than 20 years of senior management and R&D experience in the biotechnology industry. Mr. Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March 2018. From 2009 to March 2018, Mr. Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. (Nasdaq: GILD). Mr. Patel also worked at McKinsey & Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation.Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master's degree in Molecular Bioengineering/Biotechnology at the University of Washington. - Sunil Patel，在生物技术行业拥有20多年的高级管理人员和研发经验。自2018年3月以来，Patel先生一直担任生物技术公司的独立顾问，为战略和企业发展计划提供建议。2009年至2018年3月，Patel先生在OncoMed Pharmaceuticals，Inc.（纳斯达克：OMED）（一家上市的生物技术公司）担任高管职务，负责增加职责，最近担任执行副总裁兼首席财务官。Patel先生曾在BiPar Sciences，Inc.、Allos Therapeutics, Inc.、Connetics、Abgenix，Inc.和吉利德科学 Inc.（GILD）担任企业发展、市场营销和战略方面的高级管理职务。Patel先生还曾任职于麦肯锡公司，为生物技术和制药客户提供服务，曾在ZymoGenetics，Inc.和ProCyte Corporation担任科研职务。帕特尔在加州大学伯克利分校获得化学本科学位，在华盛顿大学获得分子生物工程/生物技术硕士学位。
- Sunil Patel,has more than 20 years of senior management and R&D experience in the biotechnology industry. Mr. Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March 2018. From 2009 to March 2018, Mr. Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. (Nasdaq: GILD). Mr. Patel also worked at McKinsey & Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation.Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master's degree in Molecular Bioengineering/Biotechnology at the University of Washington.
- Carolyn Bertozzi
-
Carolyn Bertozzi，自2022年起担任Omniab，Inc.董事会成员。自2015年6月以来，Bertozzi博士一直在斯坦福大学任职，目前担任Anne T.和Robert M. Bass化学教授、化学和系统生物学和放射学教授以及斯坦福ChEM-H的贝克家族联合主任。自2000年以来，Bertozzi博士还担任霍华德·休斯医学研究所的研究员，并且是劳伦斯伯克利国家实验室纳米科学研究中心Molecular Foundry的前任主任。1996年至2015年，她在加州大学伯克利分校担任化学和分子与细胞生物学教授。此前，Bertozzi博士于2017年2月至2021年8月期间担任礼来公司（纽约证券交易所代码：LLY）的董事会成员。Bertozzi博士因点击化学和生物正交化学的发展而被授予2022年诺贝尔化学奖，还被授予2022年沃尔夫化学奖。除了她的学术工作，Bertozzi博士还根据她的研究创立了多家生物技术初创公司。Bertozzi拥有哈佛大学化学本科学位和加州大学伯克利分校化学博士学位。
Carolyn Bertozzi,has served on Omniab, Inc. board of directors since 2022. Since June 2015, Dr. Bertozzi has served at Stanford University, where she is currently the Anne T. and Robert M. Bass Professor of Chemistry, a professor of Chemical and Systems Biology and Radiology and the Baker Family Co-Director of Stanford ChEM-H. Since 2000, Dr. Bertozzi has also served as an Investigator at the Howard Hughes Medical Institute and is the former Director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Previously, Dr. Bertozzi served as a member of the board of directors of Eli Lilly and Company (NYSE: LLY) from February 2017 to August 2021. Dr. Bertozzi was awarded the 2022 Nobel Prize in Chemistry for the development of click chemistry and bioorthogonal chemistry, and was also awarded the 2022 Wolf Prize in Chemistry. In addition to her academic work, Dr. Bertozzi has founded multiple biotechnology start-ups based around her research.Dr. Bertozzi holds an undergraduate degree in Chemistry from Harvard University and a Ph.D. in Chemistry from the University of California, Berkeley. - Carolyn Bertozzi，自2022年起担任Omniab，Inc.董事会成员。自2015年6月以来，Bertozzi博士一直在斯坦福大学任职，目前担任Anne T.和Robert M. Bass化学教授、化学和系统生物学和放射学教授以及斯坦福ChEM-H的贝克家族联合主任。自2000年以来，Bertozzi博士还担任霍华德·休斯医学研究所的研究员，并且是劳伦斯伯克利国家实验室纳米科学研究中心Molecular Foundry的前任主任。1996年至2015年，她在加州大学伯克利分校担任化学和分子与细胞生物学教授。此前，Bertozzi博士于2017年2月至2021年8月期间担任礼来公司（纽约证券交易所代码：LLY）的董事会成员。Bertozzi博士因点击化学和生物正交化学的发展而被授予2022年诺贝尔化学奖，还被授予2022年沃尔夫化学奖。除了她的学术工作，Bertozzi博士还根据她的研究创立了多家生物技术初创公司。Bertozzi拥有哈佛大学化学本科学位和加州大学伯克利分校化学博士学位。
- Carolyn Bertozzi,has served on Omniab, Inc. board of directors since 2022. Since June 2015, Dr. Bertozzi has served at Stanford University, where she is currently the Anne T. and Robert M. Bass Professor of Chemistry, a professor of Chemical and Systems Biology and Radiology and the Baker Family Co-Director of Stanford ChEM-H. Since 2000, Dr. Bertozzi has also served as an Investigator at the Howard Hughes Medical Institute and is the former Director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Previously, Dr. Bertozzi served as a member of the board of directors of Eli Lilly and Company (NYSE: LLY) from February 2017 to August 2021. Dr. Bertozzi was awarded the 2022 Nobel Prize in Chemistry for the development of click chemistry and bioorthogonal chemistry, and was also awarded the 2022 Wolf Prize in Chemistry. In addition to her academic work, Dr. Bertozzi has founded multiple biotechnology start-ups based around her research.Dr. Bertozzi holds an undergraduate degree in Chemistry from Harvard University and a Ph.D. in Chemistry from the University of California, Berkeley.
- John Higgins
-
John Higgins,2007年1月至2022年12月，担任Ligand制药的首席执行官。在加入Ligand之前，Higgins先生自1997年起在一家专业制药公司Connetics Corporation（Connetics）担任首席财务官，还曾在Connetics担任财务和行政以及企业发展执行副总裁，直到2006年12月该公司被Stiefel Laboratories，Inc.收购。在加入Connetics之前，他是Biocryst医药公司（纳斯达克：BCRX）执行管理团队的成员。在加入BioCryst之前，Higgins先生是投资银行公司Dillon，Read & Co. Inc.的医疗保健银行团队成员。Higgins先生在生命科学服务上市公司Bio-Techne Corporation（纳斯达克：TECH）的董事会、审计委员会以及提名和治理委员会任职。希金斯先生曾担任多家上市公司和私营公司的董事。他还担任富兰克林中心董事会副主席，该中心是明尼阿波利斯的一个非营利组织，致力于为自闭症谱系或具有相关神经多样性的人提供教育和治疗服务。希金斯以优异成绩毕业于高露洁大学，获得经济学硕士学位。
John Higgins,served as Chief Executive Officer at Ligand Pharmaceuticals from January 2007 to December 2022. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer at Connetics Corporation (Connetics), a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX). Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations and governance committee of Bio-Techne Corporation (Nasdaq: TECH), a publicly-traded life sciences services company. Mr. Higgins has served as a director on numerous public and private companies. He also serves as the vice chair of the board of trustees of Franklin Center, a non-profit organization in Minneapolis dedicated to providing educational and therapy services for those on the autism spectrum or with related neurodiversities.Mr. Higgins graduated Magna Cum Laude from Colgate University with an A.B. in economics. - John Higgins,2007年1月至2022年12月，担任Ligand制药的首席执行官。在加入Ligand之前，Higgins先生自1997年起在一家专业制药公司Connetics Corporation（Connetics）担任首席财务官，还曾在Connetics担任财务和行政以及企业发展执行副总裁，直到2006年12月该公司被Stiefel Laboratories，Inc.收购。在加入Connetics之前，他是Biocryst医药公司（纳斯达克：BCRX）执行管理团队的成员。在加入BioCryst之前，Higgins先生是投资银行公司Dillon，Read & Co. Inc.的医疗保健银行团队成员。Higgins先生在生命科学服务上市公司Bio-Techne Corporation（纳斯达克：TECH）的董事会、审计委员会以及提名和治理委员会任职。希金斯先生曾担任多家上市公司和私营公司的董事。他还担任富兰克林中心董事会副主席，该中心是明尼阿波利斯的一个非营利组织，致力于为自闭症谱系或具有相关神经多样性的人提供教育和治疗服务。希金斯以优异成绩毕业于高露洁大学，获得经济学硕士学位。
- John Higgins,served as Chief Executive Officer at Ligand Pharmaceuticals from January 2007 to December 2022. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer at Connetics Corporation (Connetics), a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX). Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations and governance committee of Bio-Techne Corporation (Nasdaq: TECH), a publicly-traded life sciences services company. Mr. Higgins has served as a director on numerous public and private companies. He also serves as the vice chair of the board of trustees of Franklin Center, a non-profit organization in Minneapolis dedicated to providing educational and therapy services for those on the autism spectrum or with related neurodiversities.Mr. Higgins graduated Magna Cum Laude from Colgate University with an A.B. in economics.
- Joshua Tamaroff
-
Joshua Tamaroff,2009年加入阿维斯塔并担任合伙人。在加入阿维斯塔之前，Tamaroff先生曾在雷曼兄弟和巴克莱银行资本的杠杆金融集团担任分析师。Tamaroff先生目前担任Cosette Pharmaceuticals，Inc.、GCM Holding Corporation、Probo Medical、Solmetex和United Biosource Corporation的董事，此前曾担任InvestorPlace Media、IWCO Direct、OptiNose，Inc.（纳斯达克：OPTN）、Organogenesis Holdings，Inc.（纳斯达克：ORGO）和WideOpenWest，Inc.（NYSE：WOW）的董事。Tamaroff先生获得了康奈尔大学的理学学士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位，在那里他是帕尔默学者。
Joshua Tamaroff,joined Avista in 2009 and serves as a Partner. Prior to joining Avista, Mr. Tamaroff worked as an Analyst in the leveraged finance group at Lehman Brothers and Barclays Capital. Mr. Tamaroff currently serves as a director of Cosette Pharmaceuticals, Inc., GCM Holding Corporation, Probo Medical, Solmetex and United BioSource Corporation, and previously served as a director of InvestorPlace Media, IWCO Direct, OptiNose, Inc. (Nasdaq: OPTN), Organogenesis Holdings, Inc. (Nasdaq: ORGO) and WideOpenWest, Inc. (NYSE: WOW).Mr. Tamaroff received a Bachelor of Science from Cornell University and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was a Palmer Scholar. - Joshua Tamaroff,2009年加入阿维斯塔并担任合伙人。在加入阿维斯塔之前，Tamaroff先生曾在雷曼兄弟和巴克莱银行资本的杠杆金融集团担任分析师。Tamaroff先生目前担任Cosette Pharmaceuticals，Inc.、GCM Holding Corporation、Probo Medical、Solmetex和United Biosource Corporation的董事，此前曾担任InvestorPlace Media、IWCO Direct、OptiNose，Inc.（纳斯达克：OPTN）、Organogenesis Holdings，Inc.（纳斯达克：ORGO）和WideOpenWest，Inc.（NYSE：WOW）的董事。Tamaroff先生获得了康奈尔大学的理学学士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位，在那里他是帕尔默学者。
- Joshua Tamaroff,joined Avista in 2009 and serves as a Partner. Prior to joining Avista, Mr. Tamaroff worked as an Analyst in the leveraged finance group at Lehman Brothers and Barclays Capital. Mr. Tamaroff currently serves as a director of Cosette Pharmaceuticals, Inc., GCM Holding Corporation, Probo Medical, Solmetex and United BioSource Corporation, and previously served as a director of InvestorPlace Media, IWCO Direct, OptiNose, Inc. (Nasdaq: OPTN), Organogenesis Holdings, Inc. (Nasdaq: ORGO) and WideOpenWest, Inc. (NYSE: WOW).Mr. Tamaroff received a Bachelor of Science from Cornell University and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was a Palmer Scholar.
- Sunil Patel
-
Sunil Patel， 在生物技术行业高级管理和研发工作上有超过19年的工作经验；现任 OncoMed Pharmaceuticals（一家发展中的公司，重点针对癌症干细胞疗法）首席财务官、企业发展和金融高级副总裁。他在BiPar Sciences、Allos Therapeutics、 Connetics、 Abgenix和Gilead Sciences的企业发展、市场和战略方面担任多个高级管理职位。他还在 McKinsey & Company工作，为生物技术和制药顾客服务；并在 ZymoGenetics和ProCyte担任多个技术研究职位。他持有加利福尼亚大学伯克利分校化学研究生学位以及华盛顿大学分子生物工程/生物技术硕士学位。
Sunil Patel,has more than 20 years of senior management and R&D experience in the biotechnology industry. Mr. Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March 2018. From 2009 to March 2018, Mr. Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. (Nasdaq: GILD). Mr. Patel also worked at McKinsey & Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation.Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master's degree in Molecular Bioengineering/Biotechnology at the University of Washington. - Sunil Patel， 在生物技术行业高级管理和研发工作上有超过19年的工作经验；现任 OncoMed Pharmaceuticals（一家发展中的公司，重点针对癌症干细胞疗法）首席财务官、企业发展和金融高级副总裁。他在BiPar Sciences、Allos Therapeutics、 Connetics、 Abgenix和Gilead Sciences的企业发展、市场和战略方面担任多个高级管理职位。他还在 McKinsey & Company工作，为生物技术和制药顾客服务；并在 ZymoGenetics和ProCyte担任多个技术研究职位。他持有加利福尼亚大学伯克利分校化学研究生学位以及华盛顿大学分子生物工程/生物技术硕士学位。
- Sunil Patel,has more than 20 years of senior management and R&D experience in the biotechnology industry. Mr. Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March 2018. From 2009 to March 2018, Mr. Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. (Nasdaq: GILD). Mr. Patel also worked at McKinsey & Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation.Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master's degree in Molecular Bioengineering/Biotechnology at the University of Washington.
- Matthew W. Foehr
-
Matthew W. Foehr， 自2011年起担任执行副总裁和首席运营官；他在管理全球研究和开发项目上有超过19年的工作经验。2011年加入Ligand之前，他是 Consumer Dermatology R&D副总裁和主管以及GlaxoSmithKline GSK。公司Stiefel 分部 Dermatology的代理首席技术官。2009年GSK以36亿买下Stiefel之后，他负责领导Stiefel和GSK的研发整合。在Stiefel Laboratories, Inc.，他曾担任全球研发运营高级副总裁；产品开发和支持高级副总裁；以及全球供应链技术服务副总裁。加入Stiefel之前，他在 Connetics Corporation担任多个高管职位， 包括技术运营高级副总裁和制造副总裁。他是多本科学出版物的作者，并申请了多项美国专利。他持有圣克拉拉大学生物理学学士学位。
Matthew W. Foehr has served as a member of Viking Therapeutics, Inc.'s Board since May 2014. He has also served as the President and Chief Executive Officer and a member of the board of directors of OmniAb, Inc. since November 2022. From February 2015 to November 2022, Mr. Foehr served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated ("Ligand"), and previously served as Executive Vice President and Chief Operating Officer of Ligand from April 2011 to February 2015. From February 2015 to May 2020, he served on the board of directors of Ritter Pharmaceuticals, Inc. (now named Qualigen Therapeutics, Inc.) and served on its audit committee and as Chair of its compensation committee. Mr. Foehr has over 25 years of experience in the pharmaceutical industry, having managed global operations, technology development and licensing, and research and development programs. From March 2010 to April 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GSK. Following GSK's $3.6 billion acquisition of Stiefel Laboratories, Inc., a pharmaceutical company, in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services from January 2007 to March 2010. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation, a pharmaceutical company, including Senior Vice President of Technical Operations and Vice President of Manufacturing. Early in his career, Mr. Foehr managed manufacturing activities and worked in process sciences at both LXR Biotechnology Inc. and Berlex Biosciences. He received his BS in Biology from Santa Clara University. - Matthew W. Foehr， 自2011年起担任执行副总裁和首席运营官；他在管理全球研究和开发项目上有超过19年的工作经验。2011年加入Ligand之前，他是 Consumer Dermatology R&D副总裁和主管以及GlaxoSmithKline GSK。公司Stiefel 分部 Dermatology的代理首席技术官。2009年GSK以36亿买下Stiefel之后，他负责领导Stiefel和GSK的研发整合。在Stiefel Laboratories, Inc.，他曾担任全球研发运营高级副总裁；产品开发和支持高级副总裁；以及全球供应链技术服务副总裁。加入Stiefel之前，他在 Connetics Corporation担任多个高管职位， 包括技术运营高级副总裁和制造副总裁。他是多本科学出版物的作者，并申请了多项美国专利。他持有圣克拉拉大学生物理学学士学位。
- Matthew W. Foehr has served as a member of Viking Therapeutics, Inc.'s Board since May 2014. He has also served as the President and Chief Executive Officer and a member of the board of directors of OmniAb, Inc. since November 2022. From February 2015 to November 2022, Mr. Foehr served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated ("Ligand"), and previously served as Executive Vice President and Chief Operating Officer of Ligand from April 2011 to February 2015. From February 2015 to May 2020, he served on the board of directors of Ritter Pharmaceuticals, Inc. (now named Qualigen Therapeutics, Inc.) and served on its audit committee and as Chair of its compensation committee. Mr. Foehr has over 25 years of experience in the pharmaceutical industry, having managed global operations, technology development and licensing, and research and development programs. From March 2010 to April 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GSK. Following GSK's $3.6 billion acquisition of Stiefel Laboratories, Inc., a pharmaceutical company, in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services from January 2007 to March 2010. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation, a pharmaceutical company, including Senior Vice President of Technical Operations and Vice President of Manufacturing. Early in his career, Mr. Foehr managed manufacturing activities and worked in process sciences at both LXR Biotechnology Inc. and Berlex Biosciences. He received his BS in Biology from Santa Clara University.
高管简历
中英对照 | 中文 | 英文- Matthew W. Foehr
Matthew W. Foehr是总裁兼首席执行官，也是Omniab，Inc.董事会成员，在管理运营、技术开发和全球研发计划方面拥有超过25年的制药行业经验。Foehr先生此前曾于2015年至2022年担任Ligand制药公司的总裁兼首席运营官，在此之前，自2011年起担任Ligand的执行副总裁兼首席运营官。在加入Ligand之前，他是葛兰素史克Stiefel事业部的副总裁兼消费者皮肤病学研发主管，以及皮肤病学代理首席科学官。继GSK于2009年收购Stiefel后，Foehr先生领导了Stiefel与GSK的研发整合。在Stiefel Laboratories，Foehr先生曾担任全球研发运营高级副总裁、产品开发与支持高级副总裁以及全球供应链技术服务副总裁。在加入Stiefel之前，Foehr先生曾在Connetics Corporation担任多个执行职务，包括技术运营高级副总裁和制造副总裁。Foehr先生在Viking Therapeutics, Inc.（一家上市的生物技术公司）的董事会任职，并于2015年起担任Ritter Pharmaceuticals，Inc.的董事，直到该公司于2020年与Qualigen治疗，Inc.合并。Foehr先生在圣克拉拉大学获得生物学学士学位。
Matthew W. Foehr,is President and Chief Executive Officer and a member of Omniab, Inc. board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020.Mr. Foehr received his BS degree in biology from Santa Clara University.- Matthew W. Foehr是总裁兼首席执行官，也是Omniab，Inc.董事会成员，在管理运营、技术开发和全球研发计划方面拥有超过25年的制药行业经验。Foehr先生此前曾于2015年至2022年担任Ligand制药公司的总裁兼首席运营官，在此之前，自2011年起担任Ligand的执行副总裁兼首席运营官。在加入Ligand之前，他是葛兰素史克Stiefel事业部的副总裁兼消费者皮肤病学研发主管，以及皮肤病学代理首席科学官。继GSK于2009年收购Stiefel后，Foehr先生领导了Stiefel与GSK的研发整合。在Stiefel Laboratories，Foehr先生曾担任全球研发运营高级副总裁、产品开发与支持高级副总裁以及全球供应链技术服务副总裁。在加入Stiefel之前，Foehr先生曾在Connetics Corporation担任多个执行职务，包括技术运营高级副总裁和制造副总裁。Foehr先生在Viking Therapeutics, Inc.（一家上市的生物技术公司）的董事会任职，并于2015年起担任Ritter Pharmaceuticals，Inc.的董事，直到该公司于2020年与Qualigen治疗，Inc.合并。Foehr先生在圣克拉拉大学获得生物学学士学位。
- Matthew W. Foehr,is President and Chief Executive Officer and a member of Omniab, Inc. board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020.Mr. Foehr received his BS degree in biology from Santa Clara University.
- Kurt A. Gustafson
Kurt A. Gustafson，自2022年11月起担任Omniab，Inc.执行副总裁、财务兼首席财务官。Gustafson先生自2022年3月起担任Legacy OmniAB的财务执行副总裁兼首席财务官。在加入OmniAB之前，Gustafson先生曾在上市的生物制药公司Spectrum Pharmaceuticals, Inc.担任执行副总裁兼首席财务官，自2013年6月起担任该职位。在加入Spectrum之前，Gustafson先生曾在上市的生物制药公司Halozyme Therapeutics, Inc.担任副总裁兼首席财务官，负责财务、信息技术、设施和人力资源。在2009年加入Halozyme之前，Gustafson先生在安进公司工作了超过18年，最近担任财务副总裁。在安进任职期间，Gustafson先生还曾担任总部位于瑞士的安进 International的财务主管、财务副总裁和首席财务官。Gustafson先生目前是临床阶段生物制药公司Xencor, Inc.的董事会成员。古斯塔夫森先生在北帕克大学获得会计学学士学位，在加州大学洛杉矶分校获得工商管理硕士学位。
Kurt A. Gustafson,has served as Omniab, Inc. Executive Vice President, Finance and Chief Financial Officer since November 2022. Mr. Gustafson had served as Legacy OmniAb's Executive Vice President, Finance and Chief Financial Officer since March 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he has held since June 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, most recently as Vice President, Finance. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the board of directors of Xencor, Inc., a clinical stage biopharmaceutical company. Mr. Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los Angeles.- Kurt A. Gustafson，自2022年11月起担任Omniab，Inc.执行副总裁、财务兼首席财务官。Gustafson先生自2022年3月起担任Legacy OmniAB的财务执行副总裁兼首席财务官。在加入OmniAB之前，Gustafson先生曾在上市的生物制药公司Spectrum Pharmaceuticals, Inc.担任执行副总裁兼首席财务官，自2013年6月起担任该职位。在加入Spectrum之前，Gustafson先生曾在上市的生物制药公司Halozyme Therapeutics, Inc.担任副总裁兼首席财务官，负责财务、信息技术、设施和人力资源。在2009年加入Halozyme之前，Gustafson先生在安进公司工作了超过18年，最近担任财务副总裁。在安进任职期间，Gustafson先生还曾担任总部位于瑞士的安进 International的财务主管、财务副总裁和首席财务官。Gustafson先生目前是临床阶段生物制药公司Xencor, Inc.的董事会成员。古斯塔夫森先生在北帕克大学获得会计学学士学位，在加州大学洛杉矶分校获得工商管理硕士学位。
- Kurt A. Gustafson,has served as Omniab, Inc. Executive Vice President, Finance and Chief Financial Officer since November 2022. Mr. Gustafson had served as Legacy OmniAb's Executive Vice President, Finance and Chief Financial Officer since March 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he has held since June 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, most recently as Vice President, Finance. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the board of directors of Xencor, Inc., a clinical stage biopharmaceutical company. Mr. Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los Angeles.
- Charles S. Berkman
Charles S. Berkman，自2022年11月起担任首席法务官、秘书。此前，Berkman先生自2015年12月起担任Legacy OmniAB董事会成员和OmniAB秘书，自2022年3月起担任Legacy OmniAB首席法务官。Berkman先生还自2018年1月起担任Ligand的高级副总裁、总法律顾问和秘书，在此之前自2007年4月起担任该公司的副总裁、总法律顾问和秘书。Berkman先生于2001年11月加入Ligand，曾担任协理总法律顾问和首席专利顾问（自2007年3月起担任秘书）。在加入Ligand之前，Berkman先生于2000年11月至2001年11月期间担任Baker & McKenzie国际律师事务所的律师。在此之前，他曾于1993年至2000年11月在Lyon & Lyon律师事务所担任律师，专攻知识产权法。伯克曼先生在得克萨斯大学获得化学学士学位，在得克萨斯大学法学院获得法学博士学位。
Charles S. Berkman,has served as Chief Legal Officer and Secretary since November 2022. Previously, Mr. Berkman had served as a member of Legacy OmniAb's board of directors and as OmniAb's Secretary since December 2015 and as Legacy OmniAb's Chief Legal Officer since March 2022. Mr. Berkman had also served as Ligand's Senior Vice President, General Counsel and Secretary since January 2018 and prior to that as its Vice President, General Counsel and Secretary since April 2007. Mr. Berkman joined Ligand in November 2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March 2007). Prior to joining Ligand, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.- Charles S. Berkman，自2022年11月起担任首席法务官、秘书。此前，Berkman先生自2015年12月起担任Legacy OmniAB董事会成员和OmniAB秘书，自2022年3月起担任Legacy OmniAB首席法务官。Berkman先生还自2018年1月起担任Ligand的高级副总裁、总法律顾问和秘书，在此之前自2007年4月起担任该公司的副总裁、总法律顾问和秘书。Berkman先生于2001年11月加入Ligand，曾担任协理总法律顾问和首席专利顾问（自2007年3月起担任秘书）。在加入Ligand之前，Berkman先生于2000年11月至2001年11月期间担任Baker & McKenzie国际律师事务所的律师。在此之前，他曾于1993年至2000年11月在Lyon & Lyon律师事务所担任律师，专攻知识产权法。伯克曼先生在得克萨斯大学获得化学学士学位，在得克萨斯大学法学院获得法学博士学位。
- Charles S. Berkman,has served as Chief Legal Officer and Secretary since November 2022. Previously, Mr. Berkman had served as a member of Legacy OmniAb's board of directors and as OmniAb's Secretary since December 2015 and as Legacy OmniAb's Chief Legal Officer since March 2022. Mr. Berkman had also served as Ligand's Senior Vice President, General Counsel and Secretary since January 2018 and prior to that as its Vice President, General Counsel and Secretary since April 2007. Mr. Berkman joined Ligand in November 2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March 2007). Prior to joining Ligand, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.
- Charles S. Berkman
Charles S. Berkman， 自2007年4月起担任公司副总裁、总法律顾问和秘书。2001年11月加入公司，之前他曾自2007年3月起担任助理总法律顾问和首席专利顾问以及秘书。加入公司之前，他从2000年11月到2001年11月在一家国际律师事务所--Baker & McKenzie 担任执业律师， 专门负责知识产权法。他持有德州大学化学理学学士学位以及德州大学法学院法律博士学位。
Charles S. Berkman,has served as Chief Legal Officer and Secretary since November 2022. Previously, Mr. Berkman had served as a member of Legacy OmniAb's board of directors and as OmniAb's Secretary since December 2015 and as Legacy OmniAb's Chief Legal Officer since March 2022. Mr. Berkman had also served as Ligand's Senior Vice President, General Counsel and Secretary since January 2018 and prior to that as its Vice President, General Counsel and Secretary since April 2007. Mr. Berkman joined Ligand in November 2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March 2007). Prior to joining Ligand, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.- Charles S. Berkman， 自2007年4月起担任公司副总裁、总法律顾问和秘书。2001年11月加入公司，之前他曾自2007年3月起担任助理总法律顾问和首席专利顾问以及秘书。加入公司之前，他从2000年11月到2001年11月在一家国际律师事务所--Baker & McKenzie 担任执业律师， 专门负责知识产权法。他持有德州大学化学理学学士学位以及德州大学法学院法律博士学位。
- Charles S. Berkman,has served as Chief Legal Officer and Secretary since November 2022. Previously, Mr. Berkman had served as a member of Legacy OmniAb's board of directors and as OmniAb's Secretary since December 2015 and as Legacy OmniAb's Chief Legal Officer since March 2022. Mr. Berkman had also served as Ligand's Senior Vice President, General Counsel and Secretary since January 2018 and prior to that as its Vice President, General Counsel and Secretary since April 2007. Mr. Berkman joined Ligand in November 2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March 2007). Prior to joining Ligand, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.
- Matthew W. Foehr
Matthew W. Foehr， 自2011年起担任执行副总裁和首席运营官；他在管理全球研究和开发项目上有超过19年的工作经验。2011年加入Ligand之前，他是 Consumer Dermatology R&D副总裁和主管以及GlaxoSmithKline GSK。公司Stiefel 分部 Dermatology的代理首席技术官。2009年GSK以36亿买下Stiefel之后，他负责领导Stiefel和GSK的研发整合。在Stiefel Laboratories, Inc.，他曾担任全球研发运营高级副总裁；产品开发和支持高级副总裁；以及全球供应链技术服务副总裁。加入Stiefel之前，他在 Connetics Corporation担任多个高管职位， 包括技术运营高级副总裁和制造副总裁。他是多本科学出版物的作者，并申请了多项美国专利。他持有圣克拉拉大学生物理学学士学位。
Matthew W. Foehr has served as a member of Viking Therapeutics, Inc.'s Board since May 2014. He has also served as the President and Chief Executive Officer and a member of the board of directors of OmniAb, Inc. since November 2022. From February 2015 to November 2022, Mr. Foehr served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated ("Ligand"), and previously served as Executive Vice President and Chief Operating Officer of Ligand from April 2011 to February 2015. From February 2015 to May 2020, he served on the board of directors of Ritter Pharmaceuticals, Inc. (now named Qualigen Therapeutics, Inc.) and served on its audit committee and as Chair of its compensation committee. Mr. Foehr has over 25 years of experience in the pharmaceutical industry, having managed global operations, technology development and licensing, and research and development programs. From March 2010 to April 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GSK. Following GSK's $3.6 billion acquisition of Stiefel Laboratories, Inc., a pharmaceutical company, in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services from January 2007 to March 2010. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation, a pharmaceutical company, including Senior Vice President of Technical Operations and Vice President of Manufacturing. Early in his career, Mr. Foehr managed manufacturing activities and worked in process sciences at both LXR Biotechnology Inc. and Berlex Biosciences. He received his BS in Biology from Santa Clara University.- Matthew W. Foehr， 自2011年起担任执行副总裁和首席运营官；他在管理全球研究和开发项目上有超过19年的工作经验。2011年加入Ligand之前，他是 Consumer Dermatology R&D副总裁和主管以及GlaxoSmithKline GSK。公司Stiefel 分部 Dermatology的代理首席技术官。2009年GSK以36亿买下Stiefel之后，他负责领导Stiefel和GSK的研发整合。在Stiefel Laboratories, Inc.，他曾担任全球研发运营高级副总裁；产品开发和支持高级副总裁；以及全球供应链技术服务副总裁。加入Stiefel之前，他在 Connetics Corporation担任多个高管职位， 包括技术运营高级副总裁和制造副总裁。他是多本科学出版物的作者，并申请了多项美国专利。他持有圣克拉拉大学生物理学学士学位。
- Matthew W. Foehr has served as a member of Viking Therapeutics, Inc.'s Board since May 2014. He has also served as the President and Chief Executive Officer and a member of the board of directors of OmniAb, Inc. since November 2022. From February 2015 to November 2022, Mr. Foehr served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated ("Ligand"), and previously served as Executive Vice President and Chief Operating Officer of Ligand from April 2011 to February 2015. From February 2015 to May 2020, he served on the board of directors of Ritter Pharmaceuticals, Inc. (now named Qualigen Therapeutics, Inc.) and served on its audit committee and as Chair of its compensation committee. Mr. Foehr has over 25 years of experience in the pharmaceutical industry, having managed global operations, technology development and licensing, and research and development programs. From March 2010 to April 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GSK. Following GSK's $3.6 billion acquisition of Stiefel Laboratories, Inc., a pharmaceutical company, in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services from January 2007 to March 2010. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation, a pharmaceutical company, including Senior Vice President of Technical Operations and Vice President of Manufacturing. Early in his career, Mr. Foehr managed manufacturing activities and worked in process sciences at both LXR Biotechnology Inc. and Berlex Biosciences. He received his BS in Biology from Santa Clara University.
- Kurt A. Gustafson
Kurt A. Gustafson，自2022年11月起担任Omniab，Inc.执行副总裁、财务兼首席财务官。Gustafson先生自2022年3月起担任Legacy OmniAB的财务执行副总裁兼首席财务官。在加入OmniAB之前，Gustafson先生曾在上市的生物制药公司Spectrum Pharmaceuticals, Inc.担任执行副总裁兼首席财务官，自2013年6月起担任该职位。在加入Spectrum之前，Gustafson先生曾在上市的生物制药公司Halozyme Therapeutics, Inc.担任副总裁兼首席财务官，负责财务、信息技术、设施和人力资源。在2009年加入Halozyme之前，Gustafson先生在安进公司工作了超过18年，最近担任财务副总裁。在安进任职期间，Gustafson先生还曾担任总部位于瑞士的安进 International的财务主管、财务副总裁兼首席财务官。Gustafson先生目前是临床阶段生物制药公司Xencor, Inc.的董事会成员。古斯塔夫森先生在北帕克大学获得会计学学士学位，在加州大学洛杉矶分校获得工商管理硕士学位。
Kurt A. Gustafson,has served as Omniab, Inc. Executive Vice President, Finance and Chief Financial Officer since November 2022. Mr. Gustafson had served as Legacy OmniAb's Executive Vice President, Finance and Chief Financial Officer since March 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he has held since June 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, most recently as Vice President, Finance. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the board of directors of Xencor, Inc., a clinical stage biopharmaceutical company. Mr. Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los Angeles.- Kurt A. Gustafson，自2022年11月起担任Omniab，Inc.执行副总裁、财务兼首席财务官。Gustafson先生自2022年3月起担任Legacy OmniAB的财务执行副总裁兼首席财务官。在加入OmniAB之前，Gustafson先生曾在上市的生物制药公司Spectrum Pharmaceuticals, Inc.担任执行副总裁兼首席财务官，自2013年6月起担任该职位。在加入Spectrum之前，Gustafson先生曾在上市的生物制药公司Halozyme Therapeutics, Inc.担任副总裁兼首席财务官，负责财务、信息技术、设施和人力资源。在2009年加入Halozyme之前，Gustafson先生在安进公司工作了超过18年，最近担任财务副总裁。在安进任职期间，Gustafson先生还曾担任总部位于瑞士的安进 International的财务主管、财务副总裁兼首席财务官。Gustafson先生目前是临床阶段生物制药公司Xencor, Inc.的董事会成员。古斯塔夫森先生在北帕克大学获得会计学学士学位，在加州大学洛杉矶分校获得工商管理硕士学位。
- Kurt A. Gustafson,has served as Omniab, Inc. Executive Vice President, Finance and Chief Financial Officer since November 2022. Mr. Gustafson had served as Legacy OmniAb's Executive Vice President, Finance and Chief Financial Officer since March 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he has held since June 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, most recently as Vice President, Finance. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the board of directors of Xencor, Inc., a clinical stage biopharmaceutical company. Mr. Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los Angeles.